Q4 2024 Ocular Therapeutix Inc Earnings Call Transcript
Key Points
- Ocular Therapeutix Inc (OCUL) received FDA approval for an amendment to their special protocol agreement for SOL-1, allowing redosing at week 52 and week 76, potentially securing a six to 12-month dosing label for AXPAXLI in wet AMD.
- The company completed randomization for the SOL-1 trial ahead of schedule, with 344 subjects enrolled across more than 100 clinical sites in the US and Argentina.
- Ocular Therapeutix Inc (OCUL) has a strong financial position with a cash balance of $392 million as of December 31, 2024, and does not intend to raise additional capital this year.
- The company is well-positioned to expand AXPAXLI into other retinal indications such as non-proliferative diabetic retinopathy and diabetic macular edema, with promising early clinical results.
- Enrollment for the SOL-R trial is progressing well, with 311 subjects enrolled as of January 10, 2025, and the trial size has been reduced from 825 to 555 subjects, enhancing capital efficiency and maintaining statistical power.
- The timeline for reporting topline data for the SOL-1 trial has been shifted to the first quarter of 2026 due to the requirement to maintain masking until week 52.
- The company faces the challenge of demonstrating AXPAXLI's durability and effectiveness in a repeat dosing setting, which is critical for regulatory approval and commercial success.
- Ocular Therapeutix Inc (OCUL) must navigate the complexities of aligning their clinical trial designs with FDA guidance, which can impact trial timelines and outcomes.
- The company is dependent on FDA feedback for advancing clinical trials in non-proliferative diabetic retinopathy and diabetic macular edema, which could affect their strategic plans.
- Despite strong financials, the company's current cash projections do not account for the impact of clinical trial activities in new indications, which could require additional resources in the future.
Good morning, and welcome to the Ocular Therapeutix fourth quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference call is being recorded and will be available for replay on the Investor Relations section of the Ocular Therapeutix website.
I would now like to turn the call over to Ocular Therapeutix's Vice President of Investor Relations, Bill Slattery Jr. Please go ahead, Mr. Slattery.
Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release and filed our annual report on Form 10-K outlining our financial results and business updates for the fourth quarter and full year of 2024 along with several updates to our registrational program for AXPAXLI in wet AMD.
Ocular Therapeutix's Executive Chairman, President, and CEO, Dr. Pravin Dugel, will summarize recent business highlights before we move to our question-and-answer session. Joining Dr. Dugel for the Q&A portion of the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
